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Abstract
Background: Miscarriage is a common complication of pregnancy occurring in 15–20 % of all clinically recognized
pregnancies. Currently, there is still no good scientific evidence to support the routine use of progestogens for the
treatment of threatened miscarriage because the existing studies were not large enough to show a significant
difference and some of them were not randomized or double-blind.
Methods: This is a double-blind, randomized controlled trial. A total of 400 patients presenting with first-trimester
threatened miscarriage will be enrolled. They will be randomized to take dydrogesterone 40 mg per os, followed by
10 mg per os three times a day or placebo until twelve completed weeks of gestation or 1 week after the bleeding
has stopped, whichever is longer. The primary outcome is the percentage of miscarriage before 20 weeks of
gestation.
Discussion: We postulate that the dydrogesterone therapy will significantly reduce the risk of miscarriage in
women with threatened miscarriage.
Trial registration: This study is registered at ClinicalTrials.gov, NCT02128685. Registered on 29 April 2014.
Keywords: Threatened miscarriage, Progestogen, Dydrogesterone, Randomized controlled trial
Background
Miscarriage is a common complication of pregnancy oc-
curring in 15–20 % of all clinically recognized pregnan-
cies [1] and it may be associated with significant physical
and psychological sequelae. Threatened miscarriage is
manifested by vaginal bleeding, with or without abdom-
inal pain, while the cervix is closed and the fetus
remains viable inside the uterine cavity.
The reasons of miscarriages are many. During the first
trimester, the most common cause of miscarriage is
embryonic chromosomal abnormality [2], although in
some cases the cause cannot be identified. Progesterone
plays a crucial role in the maintenance of pregnancy. It
is secreted by the corpus luteum that provides early
pregnancy support until placental production takes over
at 10 to 12 weeks of gestation. Low levels of circulating
progesterone have been linked to impending miscarriage
[3]. It has been postulated, therefore, that a lack of
progesterone is a cause of miscarriage rather than a sec-
ondary signal of failing pregnancy.
Treatment options for threatened miscarriage include
bed rest, the use of human chorionic gonadotropin
(hCG), uterine muscle relaxants and progestogens. Bed
rest is conventionally the most commonly used manage-
ment technique for threatened miscarriage. However,
there is little evidence of its value. A recent Cochrane
review also came to the conclusion that there is
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insufficient evidence to support a policy of bed rest to
prevent miscarriage [4]. Indeed, a lack of physical activ-
ity can lead to other complications such as thrombo-
embolic events, back pain and muscle atrophy, and
women may experience emotional, family related and
economic stress during bed rest, as well as self-blame if
they fail to comply and subsequently suffer a miscarriage.
A small randomized study conducted by Harrison [5]
showed hCG to be significantly more effective than bed
rest. Based on this finding, a double-blind, randomized,
placebo-controlled study was conducted in 183 women
with first-trimester vaginal bleeding and a viable fetus as
confirmed by ultrasound [6]. However, there was no sig-
nificant difference in the incidence of complete miscar-
riage between the hCG and placebo groups (12 % versus
11 %). The sample size of the study was smaller than
planned due to loss of patients in follow-up and it was
possible that the sample size was too small to reveal any
differences in effect between hCG and placebo. Uterine
muscle relaxing drugs, which include beta-agonists and
atropine-like antispasmodic agents, are rarely used
today. A recent search of the Cochrane Pregnancy and
Childbirth Group Trials register and Central Register of
Controlled Trials confirmed that there is insufficient evi-
dence to support their use [7].
Progestogens have been used to treat threatened mis-
carriage for many years. In 1989, Goldstein et al. pub-
lished a meta-analysis of 15 randomized controlled trials
and concluded that progesterone and its analogs are in-
effective in the maintenance of pregnancy in women
with threatened miscarriage [8]. Some recent studies
suggest that the use of progestogen is associated with re-
duction in risk of miscarriage in women with threatened
miscarriage [9–11]. It has been suggested that progester-
one potentially sustains the survival of the embryo by
shifting the immune system towards production of non-
inflammatory T-helper 2 cytokines and by increasing
nitric oxide production, thus improving blood flow and
oxygen supply [12, 13]. Progesterone also plays an
important role in keeping the myometrium quiescent, as
demonstrated by enhanced uterine contractility and sen-
sitivity to prostaglandins, after treatment with mifepris-
tone, an anti-progestogen [14].
A recent Cochrane review assessing the efficacy and
safety of progestogens in threatened miscarriage identi-
fied four trials to be included in a meta-analysis, involv-
ing 421 participants, which compared progesterone with
either placebo or no medication [15]. It concluded that
progestogen treatment for threatened miscarriage re-
duced the risk of miscarriage by 47 % with a confidence
interval consistent with a risk reduction of 21 to 65 %.
Only in a subgroup of women who were treated with va-
ginal progesterone was the treatment not statistically
effective in reducing miscarriage. It also showed no
statistically significant difference in the number of con-
genital abnormalities, pregnancy-induced hypertension
nor antepartum hemorrhage between the women who
received progestogens and those who did not. However,
it was commented that the results of this systematic re-
view should be approached with caution due to the poor
methodological quality of some of the included trials,
which were not double-blind, and the small number of
participants.
Dydrogesterone, a retro progesterone with very good
oral bioavailability, is structurally and pharmacologically
very similar to natural progesterone. It is considered suit-
able for women with threatened miscarriage as, in con-
trast to other available synthetic progestogens, it does not
have androgenic side effects in the mother (e.g., hirsutism,
acne) or estrogenic effects on the fetus [11]. It also does
not alter the normal secretory transformation of the endo-
metrium, nor inhibit the formation of progesterone in the
placenta [10]. Moreover, studies have shown that it in-
creases the proportion of progesterone-induced blocking
factor-positive cells, while stimulating the production of
T-helper 2 cytokines and inhibiting T-helper 1 cytokines
[16–20], thereby ensuring protective immunomodulation.
Regarding its safety in pregnancy, despite some early sug-
gestions that progestogens may increase the risk of con-
genital developmental disorders [21, 22], evidence from
subsequent large prospective studies and meta-analyses
indicates that any such teratogenic effects are unlikely
[23–25]. A recent review of maternal use of dydrogester-
one during pregnancy also found no evidence for an in-
creased risk of congenital malformations [26].
Hence, there is still no good scientific evidence to sup-
port the routine use of progestogens for the treatment of
threatened miscarriage because the existing studies were
not large enough and some of them were not random-
ized or double-blind. Therefore, a large randomized
double-blind trial is needed.
Objective and hypothesis
The aim of this study is to determine whether dydroges-
terone therapy reduces miscarriage in women with first-
trimester threatened miscarriage. The hypothesis is that
dydrogesterone therapy will significantly reduce the risk
of miscarriage in this group of women.
Methods
Trial design (Table 1)
This is a double-blind, randomized controlled trial. The
study will be conducted in two public hospitals in Hong
Kong: Queen Mary Hospital and Kwong Wah Hospital.
Queen Mary Hospital is the affiliated hospital of the
Faculty of Medicine, the University of Hong Kong. An
ethics approval has been obtained from the Institutional
Review Board of the University of Hong Kong/Hospital
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Authority Hong Kong West Cluster (Ref number: UW
13-292). Written informed consent will be sought from
subjects at the time of recruitment, including consents
for collection of tissue mass and for further chromo-
somal and molecular studies. The clinical trial protocol
also follows the SPIRIT 2013 checklist (Additional file 1).
Selection and withdrawal of subjects
The population will be women presenting with threatened
miscarriage between five and twelve completed weeks’ ges-
tation. Threatened miscarriage is defined as vaginal bleed-
ing, with or without abdominal pain, in a pregnant woman
with pelvic ultrasound confirming an intrauterine gesta-
tional sac or fetus(es) with positive fetal heart pulsation.
Inclusion criteria
 Age of women from 18 to 40 years at the time of
recruitment (not beyond 40th birthday)
 Absence of fever (temperature ≥38.5 °C)
 Gestation less than twelve completed weeks as
defined by pelvic ultrasound
 Presence of intrauterine gestational sac(s) if a
urinary pregnancy test is first positive within the
past 2 weeks
 Presence of intrauterine fetus(es) with positive fetal
heart pulsation or presence of intrauterine fetus(es)
with crown-rump length of less than 7 mm and no
fetal pulsation on pelvic scanning
Exclusion criteria
 Age of women older than 40 years at the time of
recruitment
 History of recurrent miscarriage defined as three or
more consecutive spontaneous miscarriages
 History of known parental chromosomal
abnormalities
 Heavy vaginal bleeding requiring surgical
intervention
 Severe abdominal pain requiring surgical
intervention
 Absence of cardiac pulsation in a fetal pole with
crown-rump length of ≥7 mm on transvaginal
scanning
 Use of hCG or progesterone treatment for
threatened miscarriage prior to recruitment
 Women with current or suspected breast or genital
cancers, hepatic disease or tumors
Treatment of subjects
Subjects who consent to participate will undergo the fol-
lowing procedures:
1. Background history*: age, race, medical history,
obstetric and gynecological history, last menstrual
period, estimated gestational age at entry
2. Clinical history and findings*: severity of symptoms
and ultrasound findings
Table 1 The schedule of enrollment, interventions and assessmentsa
Study period
Enrollment Allocation Post-allocation Close-out
Timepointb 3/2016 until present 0 Weekly until 12 completed gestational
weeks or 1 week after bleeding has stopped,
whichever is longer
20 weeks Until
delivery
24th month
Enrollment:
Eligibility screen X
Informed consent X
(List other procedures)
Allocation X
Interventions:
(Dydrogesterone) X
(Placebo) X
(List other study groups)
Assessments:
Pelvic scan, serum hCG and
progesterone
X
(Primary outcome) X
(Secondary outcomes) X X
aRecommended content can be displayed using various schematic formats. See SPIRIT 2013 Explanation and Elaboration for examples from protocols [27]
bList of specific timepoints in this row
hCG human chorionic gonadotropin
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3. Physical examination*
4. Blood for serum hCG and progesterone levels
5. Treatment: dydrogesterone (treatment group) or
placebo (control group)
*Procedures should be undertaken upon admission or
in the Early Pregnancy Assessment Clinic
By computer-generated randomization, patients will be
assigned into one of the following two groups: the pro-
gesterone and control groups. The randomization
process will be done using the computer in a 1:1 ratio in
a block of 10. Each randomization result will be put into
a sealed opaque envelop. One envelop will be opened if
a woman agrees to join the study. Both the clinicians
and patients will be blinded from the treatment given.
An unblinding procedure will be considered if there are
adverse drug reactions after treatment as deemed neces-
sary by the clinician in charge.
Patients allocated to the dydrogesterone group will
receive dydrogesterone 40 mg per os, followed by 10 mg
per os three times a day, and an identical-looking pla-
cebo will be used in the control group accordingly. Con-
comitant use of any other hormonal medications or
tocolytic agents will not be allowed. Patients will be
followed up with weekly pelvic ultrasound until twelve
completed weeks of gestation or 1 week after the bleed-
ing has stopped, whichever is longer. Blood will be taken
weekly for serum hCG and progesterone levels. The
treatment will be continued until twelve completed
weeks of gestation or 1 week after the bleeding has
stopped, whichever is longer. Any adverse effects from
drugs and the patient’s compliance will be noted during
follow-up. For serious and unexpected adverse drug re-
actions, a report on the adverse drug reaction will be
submitted to the Drug Office, Department of Health as
soon as possible but no later than seven calendar days
after first becoming known to the investigators. Non-
serious adverse reactions and expected serious adverse
reactions will be reported in a brief summary at the con-
clusion of the trial. Patients will receive a standard ante-
natal checkup and follow-up routinely in the antenatal
clinic until delivery. Written consent regarding retrieval
of pregnancy and delivery data will be sought from the
patient at the time of study entry. The obstetric out-
comes will be traced from the electronic patient record
system if the patients deliver in public hospitals. A pre-
formatted letter with replying address available will be
given to the patient at the end of the study period and is
to be filled by the private obstetrician and returned to us
after delivery. If no reply letter is received 2–3 months
after the expected date of confinement of the patient, a
letter including the patient’s authorization will be sent to
the corresponding private obstetrician to retrieve the in-
formation of the pregnancy outcomes.
Treatment will be stopped if the vaginal bleeding
becomes severe and requires surgical intervention, or a
diagnosis of silent miscarriage is confirmed upon a follow-
up scan (i.e., the gestational sac or fetal pole fails to grow
after 1 week, or there is no cardiac activity in a fetal pole
with crown-rump length of ≥7 mm). If the patient has a
spontaneous miscarriage, the tissue mass passed or ob-
tained after medical or surgical evacuation will be sent for
histology and karyotyping by quantitative fluorescence-
polymerase chain reaction (QF‐PCR) or the array com-
parative genomic hybridization method. QF-PCR, which
is a simple and cheap method, will first be used to exclude
common aneuploidy of chromosomes 13, 18, 21 and XY.
The array comparative genomic hybridization method will
be employed in those with negative QF-PCR results to
confirm or exclude aneuploidy.
The primary outcome is the percentage of miscarriages
before 20 weeks of gestation. The secondary outcomes
are the live birth rate; the proportion of heavy vaginal
bleeding or severe abdominal pain requiring surgical
intervention (after 20 weeks); and obstetric complica-
tions including antepartum hemorrhage, placenta previa,
pregnancy-induced hypertension, intrauterine death,
congenital abnormality, preterm labor, and low birth
weight at term. The birth weight, gestational age at de-
livery and apgar score are also included. The definitions
of the obstetric complications are as follows:
 Antepartum hemorrhage: any vaginal bleeding
during pregnancy from the 24th week of gestational
age to term
 Placenta previa: placenta inserting partially or wholly
in the lower uterine segment, diagnosed by antenatal
ultrasound at the second and third trimesters
 Pregnancy-induced hypertension: development of
new-onset hypertension (blood pressure persistently
140/90 mmHg or higher on two occasions at least
4 hours apart) during pregnancy after 20 weeks’
gestation, labor or the puerperium in a previously
normotensive non-proteinuric women
 Intrauterine death: fetal death in utero after
24 weeks’ gestation
 Preterm labor: any premature spontaneous delivery
from 24 weeks’ to 36 weeks’ gestation
 Low birth weight at term: baby born with birth
weight less than 2500 g at or after 37 weeks’
gestation
In order to increase the generalizability of our results,
we do not exclude subjects with multiple pregnancy and
uterine anomaly, and we also include pregnancy of un-
certain viability. However, this decision may potentially
increase the heterogenicity of the results and this may
be one of the limitations of the study.
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Statistics
Statistical tests
All statistical analyses will be performed using IBM SPSS
software using intention-to-treat and per protocol ana-
lyses. Nominal data will be described by frequencies and
percentages, and correlations will be analyzed using the
chi-square test; continuous data will be expressed as
mean ± standard deviation or median (range), and ana-
lyzed using Student’s t test or the Mann-Whitney U test
depending on the normality of the data. The primary
outcome, the percentage of miscarriage before 20 weeks
of gestation, will be analyzed with the chi-square test.
Subgroup analysis for the primary outcome will be done
with regard to gravida, gestation at presentation, pres-
ence of subchorionic hematoma and after exclusion of
those with an abnormal karotype in the abortus. The
secondary outcomes will be compared between the treat-
ment group and the control group by the chi-square test.
Logistic regression analysis will be performed to find out
the independent predictive factors for miscarriage. A p
value <0.05 will be considered as statistically significant.
Every attempt will be made to collect full follow-up data
on all women (unless a woman withdraws consent for
follow-up data collection). In particular, women will be
followed up even after protocol violation. It is thus antici-
pated that missing data will be minimal. Women with
missing primary outcome data will not be included in the
primary analysis. This presents a risk of bias, and second-
ary sensitivity analyses will be undertaken to assess the
possible impact of the risk, including the assumption that
all women lost to follow-up have miscarriages before
20 weeks. Other sensitivity analyses will involve simulating
missing responses using a multiple imputation.
Sample size estimation
Based on the two previous studies [11, 12], with the pooled
miscarriage rate in the progestogen group and control
group being 27/182 (14.8 %) versus 42/155 (27.1 %), re-
spectively, a sample size of 171 per group is needed to
achieve a power of 80 % with a type I error of 0.05. To
allow for drop out, we plan to recruit 400 subjects in total
with 200 patients in each arm.
Discussion
The control group will only receive placebo in this study.
Currently, there is still no good scientific evidence to
support the routine use of progestogens for the treat-
ment of threatened miscarriage because the existing
studies were not large enough to show a significant dif-
ference and some of them were not randomized or
double-blind. Currently, we are not offering any drug
treatment in public hospitals in Hong Kong for patients
presenting with threatened miscarriage, which is the way
that subjects in the control group will be managed.
Hence, there is no ethical concern in this regard.
In order to increase the generalizability of our results,
we do not exclude subjects with multiple pregnancies
and uterine anomaly, and we also include pregnancy of
uncertain viability. However, this decision may poten-
tially increase the heterogenicity of the results and this
may be one of the limitations of the study.
Trial status
The study was started in March 2016. An ethics approval
has been obtained from the Institutional Review Board of
the University of Hong Kong/Hospital Authority Hong
Kong West Cluster (Ref number: UW 13-292).
Additional file
Additional file 1: SPIRIT fillable-checklist-miscarriage. (DOC 97 kb)
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